Key Highlights

● Revenue rose year over year and from the second quarter

● Tablo console sales led growth

● GAAP net loss narrowed

● Annual Revenue and Margin outlook was repeated

Outset Medical, Inc. (NASDAQ:OM) added to a busy reporting week for smaller healthcare equities, posting third-quarter revenue that rose from the prior-year period by a mid-teens rate and from the second quarter by a mid-single-digit rate. The San Jose, California, maker of the Tablo Hemodialysis System also reiterated its full-year revenue guidance and its expectation for gross margin, according to the Earnings release it filed with the US Securities and Exchange Commission.

The company's net loss narrowed on a GAAP basis, both in total and per share. Its non-GAAP net loss was little changed in total from the prior-year period, and it edged lower per share. The company excludes stock-based compensation and litigation charges tied to a stockholder class action and related derivative suits from its non-GAAP results, and the distance between the GAAP and non-GAAP loss was much narrower than a year earlier.

The third-quarter result also marks a contrast with the start of the year. Revenue in the first quarter declined from the prior-year period, with product revenue down and Recurring Revenue about flat. Through the end of September, revenue is now slightly ahead of the same period last year, which means the second half is carrying the company's annual growth, as management had signaled during the summer.

Consoles Led, Recurring Revenue Followed

The growth came from both parts of the Tablo business, with Capital sales in the lead. Console revenue climbed by more than a quarter compared with the prior-year period and by about a tenth sequentially. Recurring revenue, which consists of Tablo consumables and services, increased by about a tenth from a year earlier and by a smaller amount from the second quarter. Recurring revenue remains the larger portion of the business, at more than half of the total.

The income statement presents the same revenue in a different cut. Product revenue rose by a mid-teens rate, and service and other revenue increased by a low double-digit rate. Across the first part of the year, product revenue slipped slightly while service revenue grew, showing again how much the most recent quarter contributed to the turnaround in capital and consumable sales.

Chair and Chief Executive Leslie Trigg credited "solid sales execution across both capital and recurring revenue." She said that "consistently strong customer satisfaction and retention are expanding adoption of Tablo" among existing customers, "and fueling new insourced dialysis partnerships with leading health systems." The release does not name those new partners or quantify them.

The recurring line had drawn questions a quarter earlier. On the second-quarter call, Chief Financial Officer Renee Gaeta attributed a drop in consumable revenue to a tough prior-year comparison and to ordering timing, and described "nothing alarming or concerning" in the trend, while Trigg said utilization showed "no material changes." The third-quarter increase in recurring revenue is consistent with that account, although a single quarter does not settle the matter.

Margin Details Show a Change in Mix

Gross margin expanded from the prior-year period by a little more than a percentage point on a GAAP basis, and non-GAAP gross margin was only a touch higher. Beneath that total, the revenue streams moved in opposite directions. Product gross margin slipped from the prior-year period, while service gross margin improved sharply. In other words, the service improvement explains the overall gain, despite product revenue growing faster.

The sequential trend needs a separate reading. Gross margin for the year to date stands above the third-quarter figure on both a GAAP and non-GAAP basis, and the first-quarter margin was also higher. The third quarter therefore delivered a lower margin than the earlier part of the year, even as it delivered the higher revenue. The release does not attribute that movement to a particular cause. The heavier console contribution is a possible Factor to watch, given that product margin fell, but the company did not say so in the text reviewed.

Management continues to expect full-year non-GAAP gross margin in a range running from the low forties to the mid forties, the same framing it used earlier this year. Gaeta said on the second-quarter call that the company is on track toward its "next milestone" of a substantially higher company-wide gross margin, without giving a date. That goal remains well above the current level, so the margin path is still more aspiration than achievement.

The quarterly progression makes this clearer. Product gross margin in the first quarter stood well above the third-quarter level, while service gross margin climbed over the same span. Non-GAAP gross margin also eased from the second quarter to the third. Service margins have therefore been improving through the year, even as product margins have narrowed from their early-year high.

Spending Discipline and the Loss Line

Total operating expenses fell by a mid-single-digit rate from the prior-year quarter. Sales and Marketing was the largest category, followed by general and administrative costs and then research and development. Stock-based compensation and litigation charges were relatively small contributors in the quarter, and non-GAAP operating expenses stood only modestly below the GAAP total.

Lower spending and higher Gross Profit together narrowed the operating loss from the prior-year figure. The company's forward-looking statements refer to the anticipated impacts of its cost reduction actions and restructurings, which suggests that the cost base remains an active area of management attention. They also refer to the evolution of its commercial model, including changes to its sales organization and incentives.

Those phrases connect to remarks from the second-quarter call. Trigg said near-term priorities included adding sales talent and expanding coverage toward the largest health systems in the country, and said the company is "scaling that foundation to increasingly execute with consistency, conversion, and impact." The Operating Expense trend will show how the added sales coverage and the cost reductions balance out.

The first-quarter release offers a useful comparison. Operating expenses at that stage were higher than in the third quarter, and they had risen from the prior-year period, so the third-quarter decline marks a change in direction. The GAAP net loss also came in smaller than in the first quarter, helped by the additional revenue.

Cash Burn Against a Narrowing Cushion

Liquidity is the critical counterweight to the growth story. Net cash used in the quarter was slightly above the second-quarter figure, and total cash, cash equivalents, short-term investments and restricted cash fell from the second-quarter balance. That total has declined in each of this year's reports, moving from the first-quarter level to the second-quarter level and then to the current one.

On the second-quarter call, management targeted full-year cash use below a stated ceiling. Adding the cash use disclosed so far this year produces a sum that sits below that ceiling, leaving a modest remaining allowance for the fourth quarter. The company's latest release did not repeat the target in the sections reviewed, so this comparison relies on the earlier statement.

Debt also forms part of the picture. A term Loan was outstanding at the end of September, and total liabilities were well above that figure. Stockholders' Equity fell considerably from the end of last year, consistent with continued net losses. Short-term investments make up most of the company's liquidity, with a smaller amount held in cash and equivalents.

The forward-looking statements mention the sufficiency of cash balances through cash-flow breakeven, which is the outcome the company is working toward. Trigg referred on the second-quarter call to "a clear path to profitability," but no breakeven date or runway estimate was given in that discussion.

What Repeated Guidance Implies for the Final Quarter

Outset reiterated its full-year revenue range. Comparing that range with the revenue already recorded for the year gives a useful sense of what the guidance requires. Subtraction shows the low end implies fourth-quarter revenue slightly below the third-quarter level, while the high end requires a meaningful sequential increase. The middle of the range sits a little above the third-quarter result.

That arithmetic fits the seasonal pattern management described in August. Gaeta said at that time that most of the year's growth was expected in the third and fourth quarters, that the third quarter could see seasonality, and that the final quarter is typically the stronger one for the company. That remark does not specify an amount, but it indicates the direction management anticipated.

The first quarter's release framed the annual range as growth at a mid-to-high single-digit pace from last year's revenue. Holding the range through each report this year, during a period when the first quarter fell short of the prior year and the third quarter rose strongly, suggests management's view of the year has remained steady. No increase was offered, and no reduction either.

Where the Tablo Platform Stands

Tablo combines water purification and on-demand dialysate production within a single integrated system. It is cleared by the FDA for use from hospital to home, according to the company, and is used by a large number of healthcare facilities in the United States, and the company says it has supported millions of treatments. It connects to electronic medical record systems and a proprietary Data Analytics platform. The company describes its mission as reducing the cost and complexity of dialysis.

In January, Outset said the FDA had cleared its next-generation Tablo platform through the premarket notification process. The company said Tablo is the first hemodialysis system to incorporate the agency's Cybersecurity guidance from June of last year, with security built into the hardware, software and cloud layers. Other changes included operating system updates, hardware upgrades and software improvements meant to extend the time between planned maintenance in high-acuity settings, plus a redesigned exterior for acute care environments. At the time, it expected shipments to begin in the second quarter and said existing users could upgrade.

By the August call, the platform was in a pilot phase. Trigg said the company wanted to "really, really, really get this right" and would review pilot data before a full launch, with no timeline given. The third-quarter highlights do not address this launch, and the forward-looking statements refer only generally to the anticipated launch and timing of product enhancements and new features, so the current status is not established by the release.

Trigg said in January that the company was "proud to be the first dialysis company to clear the high standard for cybersecurity set by the FDA," and that the platform was designed "to protect and amplify the clinical, financial and operational value" of the system. The January release described hospitals, health systems and home dialysis providers as the intended customers.

Insourcing Is the Commercial Thread

Hospital dialysis insourcing is central to how management describes the opportunity. On the second-quarter call, Trigg said the company's agreement with HCA "reinforces" the long-term commitment of both parties to insourced dialysis, with that arrangement running through a coming year. The latest release returns to the same theme by citing new insourced partnerships with leading health systems. Trigg framed the wider aim as helping providers "improve the cost, complexity and clinical outcomes of dialysis."

The company's Securities and Exchange Commission filing lists macroeconomic conditions, FDA and other regulatory matters and changes in Tariff or trade policy among factors that could affect its forward-looking statements. It refers readers to the risk factors in its filings for a fuller list. The tariff reference is relevant for a hardware business, although the release offers no estimate of the effect.

Open Items Ahead of Year-End

Several issues are likely to define how the quarter is judged in hindsight.

The first is whether the fourth quarter delivers the sequential strength management has described. The next is whether gross margin can recover toward the level seen earlier this year while consoles take a larger share of the mix. Another is the rate at which cash declines, given the term loan outstanding and the company's stated goal of reaching breakeven on its current balances.

The third-quarter call took place on the same afternoon as the release, and an archived version is available through the company's investor site.